| 1) Methodological differences (use of anesthesia, stretch methodology, et |
| 2) s), (b) factors linked to implementation (use of manuals, training of implementers a |
| 3) Time-use of older adults can be different than |
| 4) Use of diabetes technology is associated w |
| 5) Use of information technology could be inc |
| 6) Use of personal protective equipments and |
| 7) Use of the method allows the detection of |
| 8) nce regarding asepsis include the topical use of >0.5% chlorhexidine preparation |
| 9) This scoping review explored the use of ACT as an intervention to support a |
| 10) They explored the use of AI in cleft lip and/or palate to ai |
| 11) tions to contribute to a more responsible use of AI technologies in dentistry. |
| 12) the body of literature investigating the use of AMF data to predict morbidity and m |
| 13) mplications for clinical protocols in the use of Botulinum Toxin in children with ce |
| 14) fulness-based clinical trials allowed the use of CADTs. |
| 15) d that there is limited literature on the use of DHT to enable remote care in respon |
| 16) Several studies report on the use of EPAs to evaluate different curricul |
| 17) d and aphasic language processing and the use of ERPs with PWA. |
| 18) The use of GLP-1 analog was able to decrease b |
| 19) ns generally have positive regard for the use of HTN guidelines to achieve HTN treat |
| 20) ithout genotyping error, complicating the use of HWE testing to assess genotype data |
| 21) ations provide additional support for the use of MRD as a surrogate end point for PF |
| 22) recent European Medicines Agency-approved use of MSCs in Crohn-related fistular dise |
| 23) sponders and quantify how first responder use of N95 respirators and patient use of |
| 24) Although use of NAMs for higher level regulatory de |
| 25) ies are required to address the potential use of NC and WrC as predictors of early m |
| 26) We conclude that the use of NC and WrC, in addition to other we |
| 27) ed 33 primary articles that described the use of NEPIs. |
| 28) aims to explore the current evidence for use of NEWS in community settings. |
| 29) n regarding non-medical and extra-medical use of NSAIDs. |
| 30) ho engage in non-medical or extra-medical use of NSAIDs; (2) antecedents for non-med |
| 31) en into consideration when optimizing the use of NTX in the pediatric population. |
| 32) e decades-old bans on the manufacture and use of PCBs. |
| 33) Finally, we illustrate the use of PCovR2 by means of empirical data. |
| |